$ANNX News
Last published 2d ago
- 2d agoANNXAnnexon, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 2d agoANNXAnnexon Reports Third Quarter 2026 Financial Results, Business Updates and Key Anticipated MilestonesGlobeNewswireDifferentiated C1q Platform Advances Two Registrational Programs with Blockbuster Potential, Driving Near-Term Value Catalysts Tanruprubart U.S./EU FORWARD Data in GBS Strengthens BLA Submission Package Anticipated in
- 2d agoANNXAnnexon Reports Third Quarter 2026 Financial Results, Business Updates and Key Anticipated MilestonesGlobeNewswireDifferentiated C1q Platform Advances Two Registrational Programs with Blockbuster Potential, Driving Near-Term Value Catalysts
- 2w agoANNXAnnexon to Host Virtual Investor Event on November 3, 2026: Vonaprument for the Treatment of Geographic Atrophy - Highlighting Key Aspects of Phase 3 ARCHER II TrialGlobeNewswireBRISBANE, Calif., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that
- 3w agoANNXAnnexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBRISBANE, Calif., Oct. 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that
- 1mo agoANNXAnnexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBRISBANE, Calif., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that
- 2mo agoANNXWELLS FARGO 21ST ANNUAL HEALTHCARE CONFERENCE - ANNEXON INCEarnings Call TranscriptsGood morning, everyone. Thanks so much for joining us. We'll get going here on the next Fireside Discussion. My name is Derek Archul. I'm one of the Wells Fargo biotech analysts. Very excited to have the team from Annexo
- 2mo agoANNXWELLS FARGO 21ST ANNUAL HEALTHCARE CONFERENCE - ANNEXON INCEarnings Call TranscriptsGood morning, everyone. Thanks so much for joining us. We'll get going here on the next Fireside Discussion. My name is Derek Archul. I'm one of the Wells Fargo biotech analysts. Very excited to have the team from Annexo
- 2mo agoANNXAnnexon to Participate in Upcoming September Investor ConferencesGlobeNewswireBRISBANE, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that
- 2mo agoANNXAnnexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBRISBANE, Calif., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that
- 3mo agoANNXAnnexon Reports Second Quarter 2026 Financial Results, Business Updates and Key Anticipated MilestonesGlobeNewswireRapid, Positive Clinical Outcomes in GBS FORWARD Study Reinforce Consistency and Reproducibility of Tanruprubart Treatment Effect Demonstrated in Phase 3 and Real-World Evidence Studies; BLA Submission Expected in Q4
- 3mo agoANNXAnnexon Expands Vonaprument Phase 3 Program in Geographic Atrophy with Addition of Month 24 Dual Primary Endpoint Complementing Month 15 Primary Endpoint and Launch of Open-Label Extension StudyGlobeNewswireBRISBANE, Calif., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies for multiple neuroinflammatory diseases
- 3mo agoANNXAnnexon Appoints Renowned Retinal Surgeon and Biotechnology Entrepreneur Mark S. Blumenkranz, M.D., M.M.S. to its Board of DirectorsGlobeNewswireBRISBANE, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies for multiple neuroinflammatory diseases
- 3mo agoANNXAnnexon Reports First U.S. and European Patient Cohort of GBS FORWARD Study Demonstrated Rapid, Positive Clinical Responses in All Tanruprubart Treated Patients Within One WeekGlobeNewswireEarly Outcomes Reinforce the Consistency and Reproducibility of Tanruprubart Treatment Effect Previously Demonstrated in Phase 3 and Real-World Evidence Studies Potential to Become the First Approved Targeted Therapy
- 3mo agoANNXAnnexon Secures Strategic Credit Facility for up to $200 Million from Oxford FinanceGlobeNewswireBRISBANE, Calif., July 30, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies for multiple neuroinflammatory diseases
- 3mo agoANNXAnnexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBRISBANE, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that
- 4mo agoANNXAnnexon to Present Phase 2 ARCHER Baseline Characteristics Associated with Confirmed Best Corrected Visual Acuity 15-Letter Loss in Patients with Geographic Atrophy at ASRS 2026GlobeNewswireBRISBANE, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that
- 4mo agoANNXAnnexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBRISBANE, Calif., June 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that
- 5mo agoANNXAnnexon, Inc. - Jefferies Global Healthcare Conference in New York - ANNEXON INCEarnings Call TranscriptsReady for our next session. I'm Andrew Tsai, Senior Biotech Analyst at Jefferies. Thanks for joining us. And it's my pleasure to have the Annexon team with me. To my direct left is Doug Love, President, CEO, and to his l
- 5mo agoANNXAnnexon to Participate in Upcoming June Investor ConferencesGlobeNewswireBRISBANE, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that
- 5mo agoANNXAnnexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBRISBANE, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that
- 6mo agoANNX2026 GLOBAL HEALTHCARE CONFERENCE - ANNEXON INCEarnings Call TranscriptsOkay, good afternoon or still good morning, I think. Welcome back to the Bank of America Healthcare Conference. I'm Tazina Mudd. I am one of the Senior Biotech Analysts at the Bank. It's my pleasure to have our next pres
- 6mo agoANNX110 Years. 110 Stories. 110 Reasons to Raise Awareness for GBSGlobeNewswireCONSHOHOCKEN, Pa., May 11, 2026 (GLOBE NEWSWIRE) -- May is GBS|CIDP Awareness Month and this year marks 110 years since the discovery of Guillain-Barré syndrome (GBS), which was first identified and named in 1916
- 6mo agoANNXAnnexon Reports First Quarter 2026 Financial Results, Portfolio Progress and Key Anticipated MilestonesGlobeNewswireTopline Pivotal Phase 3 Data for Vonaprument for the Treatment of Geographic Atrophy (GA) Expected Q4 2026, with Potential to Redefine Vision Preservation in GA Tanruprubart EU Marketing Authorization Application (MAA)
- 6mo agoANNXAnnexon to Present at the Bank of America Securities Health Care Conference 2026GlobeNewswireBRISBANE, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that
- 7mo agoANNXAnnexon to Present at the 25th Annual Needham Virtual Healthcare ConferenceGlobeNewswireBRISBANE, Calif., April 08, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that
- 7mo agoANNXAnnexon Reports Fourth Quarter and Year-End 2025 Financial Results, Portfolio Progress and Key Anticipated MilestonesGlobeNewswireARCHER II Topline Pivotal Phase 3 Data in Geographic Atrophy (GA) Expected Q4 2026; Vonaprument has Potential to Be the First Vision-Preserving Therapy for GA Tanruprubart MAA Filed in Europe with Potential to Be the
- 8mo agoANNXAnnexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBRISBANE, Calif., March 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that
- 8mo agoANNXAnnexon Biosciences to Present at the TD Cowen 46th Annual Health Care ConferenceGlobeNewswireBRISBANE, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that
- 8mo agoANNXAnnexon to Host In-Person and Virtual KOL Event to Discuss Vonaprument for the Treatment of Geographic AtrophyGlobeNewswireBRISBANE, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that
- 9mo agoANNXAnnexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBRISBANE, Calif., Jan. 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that
- 10mo agoANNXAnnexon Accelerating Next Generation Targeted Immunotherapy Platform for Treatment of Neuroinflammatory Diseases with Multiple Registrational Milestones in 2026GlobeNewswireTanruprubart MAA Filed with Potential to Be the First Targeted Fast-Acting Therapy for Guillain-Barré Syndrome (GBS); BLA Submission with U.S./European Data Planned in 2026 Vonaprument Pivotal Phase 3 Topline Data for
- 10mo agoANNXAnnexon Submits Tanruprubart Marketing Authorization Application to the European Medicines Agency for Guillain-Barré SyndromeGlobeNewswirePotential to Be the First Targeted Fast-Acting Therapy for GBS, Setting a New Standard of Care BLA Submission with U.S./European Data from FORWARD Trial Planned in 2026 BRISBANE, Calif., Jan. 08, 2026 (GLOBE
- 10mo agoANNXAnnexon Biosciences to Present at the 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswireBRISBANE, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that
- 11mo agoANNXAnnexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBRISBANE, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. ("Annexon") (NASDAQ:ANNX), a biopharmaceutical company advancing a late-stage clinical platform targeting neuroinflammation across life-changing
- 12mo agoANNXAnnexon Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $86.25 MillionGlobeNewswireBRISBANE, Calif., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. ("Annexon") (NASDAQ:ANNX), a biopharmaceutical company advancing a late-stage clinical platform targeting neuroinflammation across life-changing
- 12mo agoANNXAnnexon Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded WarrantsGlobeNewswireBRISBANE, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. ("Annexon") (NASDAQ:ANNX), a biopharmaceutical company advancing a late-stage clinical platform targeting neuroinflammation across life-changing
- 12mo agoANNXAnnexon Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsGlobeNewswireBRISBANE, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing a late-stage clinical platform targeting neuroinflammation across life-changing complement-mediated
- 1y agoANNXAnnexon Reports Third Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated MilestonesGlobeNewswireLate-Stage Neuroinflammation Platform Advancing Global Registrational Programs in Guillain-Barré Syndrome (GBS) and Geographic Atrophy (GA) Current Tanruprubart GBS Dossier On Track for MAA Filing in January 2026;
- 1y agoANNXAnnexon, Inc. (ANNX) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 TranscriptEarnings Call Transcripts
- 1y agoANNXAnnexon, Inc. (ANNX) Presents at Cantor Global Healthcare Conference 2025 TranscriptEarnings Call Transcripts
- 1y agoANNXAnnexon Biosciences to Participate in Upcoming September Investor ConferencesGlobeNewswireBRISBANE, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical
- 1y agoANNXAnnexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBRISBANE, Calif., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical
- 1y agoANNXAnnexon Reports Second Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated MilestonesGlobeNewswireTanruprubart (formerly ANX005) for GBS Advancing Through Regulatory Interactions; MAA Submission in Europe Anticipated in First Quarter of 2026; Ongoing Discussions with FDA Regarding Generalizability Package to Support
- 1y agoANNXAnnexon Selected by EMA to Participate in Product Development Coordinator Pilot for Vonaprument (ANX007) for Dry Age-Related Macular Degeneration with Geographic AtrophyGlobeNewswireNew Pilot Appoints Designated Product Development Coordinator to Navigate Regulatory Interactions, Respond to Ad-hoc Queries, and Support Evidence Planning Vonaprument Selected by EMA as One of ~20 PRIME Development
- 1y agoANNXAnnexon Announces Completion of Enrollment in Pivotal Phase 3 ARCHER II Trial of Vonaprument (formerly ANX007) for Dry Age-Related Macular Degeneration (AMD) with Geographic AtrophyGlobeNewswireExpedited Enrollment Surpassing 630 Targeted Participants Underscores the Strong Demand for a Therapy Focused on Vision Preservation Phase 3 ARCHER II Trial Design and Rationale to Be Presented at ASRS, a Leading
- 1y agoANNXAnnexon Bolsters Ophthalmology Expertise with Appointment of Retina Specialist Lloyd Clark, M.D., as Pivotal ANX007 Program Advances in Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy (GA)GlobeNewswireDr. Clark Brings 25 Years of Experience Treating Retina Diseases and Developing Emerging Therapies as a Principal Investigator in Over 70 Clinical Trials and as an Early Pioneer of VEGF Inhibitors ANX007 is the Only
- 1y agoANNXAnnexon Biosciences to Present at the Jefferies Global Healthcare ConferenceGlobeNewswireBRISBANE, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical
- 1y agoANNXAnnexon Showcases Tanruprubart Data Demonstrating Improved Clinical Outcomes in Guillain-Barré Syndrome (GBS) at 2025 Peripheral Nerve Society (PNS) Annual MeetingGlobeNewswireFirst Oral Presentation of the Tanruprubart Real-World Evidence (RWE) Study by International Guillain-Barré Syndrome Outcomes Study (IGOS) Researchers Highlights Benefits over Current Standard of Care in Matched Patient
- 1y agoANNXAnnexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBRISBANE, Calif., May 16, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical